Objective: We evaluated the cross-sectional association between restless legs syndrome (RLS) and prevalent cardiovascular disease (CVD) in a large community-based sample of middle-aged and elderly subjects.
typed, brief (0.5 to 5.0 seconds) movements of the lower extremities, which are associated with autonomic activation 4 and variable EEG arousal. 5 Two previous epidemiologic studies have suggested an association of cardiovascular disease (CVD) with RLS. 6, 7 However, these studies did not use currently accepted criteria for RLS diagnosis, and one only evaluated men. The basis for a relation between RLS and CVD may be the repetitive EEG arousals or substantial autonomic hyperactivity during sleep observed in patients with RLS and associated PLMS. Alternatively, sleep deprivation, a common consequence of RLS, may play a role in the association with CVD. 8 We examined the relation between CVD and RLS using the large community-based middle aged and elderly cohort of the Sleep Heart Health Study (SHHS).
METHODS Study sample. Participants in the SHHS, a community-based prospective cohort study of the cardiovascular consequences of obstructive sleep apnea/hypopnea (OSAH), 9 were the subjects of this study. Of 6,441 subjects who were first examined between 1995 and 1998, 4,586 subjects (71%) participated in a second SHHS examination between 2000 and 2003. At this SHHS-2 examination, blood pressure and body habitus were measured and questionnaire data were obtained regarding sleep habits and symptoms, medication use, and history of cardiovascular disease. Overnight polysomnography was performed in 3,078 subjects (67% of SHHS-2 participants). Of the 4,586 SHHS-2 participants, 477 were excluded for missing data on RLS symptoms and an additional 576 for other missing key variables. Another 100 subjects were excluded because they reported a history of CAD or CVD at the first SHHS examination but reported no history of CAD or CVD at the second SHHS examination. The protocol was approved by the Institutional Review Board of each participating center and signed informed consent was provided by each subject.
Restless legs syndrome symptoms. RLS was identified from responses to a series of questions asked as part of the SHHS-2 Health Interview Questionnaire. These questions were developed using the NIH diagnostic criteria. 1 Specifically, positive responses to the following three "yes/no" questions were required: "In the past year, while sitting or lying down, have you had the urge to move your legs?"; "Are they worse when you are sitting or lying down than when you are moving around or walking"; "Do the symptoms improve if you get up and start walking?" Subjects were additionally given multiple choices of activity level during symptom appearance: 1) "resting, sitting, or lying down"; 2) "exercising or just stopped exercising"; 3) "standing or walking"; or 4) "having a leg cramp or 'charley horse'." To meet criteria for RLS, subjects must have answered number 1 only. In addition, a question was asked about the time of symptoms, with the possible answers of "daytime only," "bedtime only," "evening or nighttime," and "both day and night." RLS was diagnosed only if the participant endorsed the responses "bedtime only" or "evening or nighttime," or, if "both day and night" was endorsed, the participant also responded positively to a follow-up question "if both day and night, do they get worse at night?" Additional questions regarding the frequency of these symptoms ("less than once a month," "about once a month," "2-4 days a month," "5-15 days a month," "most days [16 -23 days a month]," "daily [6 days a week or more])," and the salience of these symptoms ("How bothersome or troublesome is this symptom?" with options of "hardly at all," "a little," "moderately," "a lot," "extremely"), were also addressed. Symptomatic RLS was defined as symptoms occurring at least 5 to 15 days per month, with at least moderate distress. Duration of RLS symptoms in years was estimated from the question "How old were you when you first noticed these symptoms?" Prevalent cardiovascular disease. Prevalent coronary artery disease (CAD) was defined as a self-reported history of doctor-diagnosed angina, myocardial infarction, or coronary revascularization procedures on an intervieweradministered questionnaire prior to the SHHS-2 examination. CVD was defined as CAD or a history of physician-diagnosed stroke or heart failure reported on this same instrument.
Additional questionnaire data. A self-completed Sleep
Habits Questionnaire was used to obtain measures of usual sleep latency, sleep duration, nocturnal leg movements, insomnia ("trouble falling asleep," "difficulty getting back to sleep" after nighttime awakenings, early morning awakenings with inability to get back to sleep), smoking habits, and usual caffeine and alcohol consumption. For analysis, insomnia was operationally defined as a response of 16 to 30 nights per month for any of the three insomnia symptoms. Medication use was ascertained using a standardized medication survey as previously described. 10 Diabetes mellitus (DM) was defined as current use of insulin or oral hypoglycemic agents.
Other physical measurements. Three seated blood pressure measurements were taken at 5-minute intervals as part of the SHHS-2 examination. For this analysis, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were obtained by taking the mean of the second and third blood pressure measurements. Hypertension was defined as SBP Ն140 or DBP Ն90 mm Hg, or current use of antihypertensive medication. Unattended, in-home polysomnography was performed on the night of a home visit, as previously described. 11 The apnea-hypopnea index was defined as the number of apneas plus hypopneas, each associated with at least a 4% decrease in oxyhemoglobin saturation, per hour of sleep. A dichotomous variable indicating the presence or absence of obstructive sleep apnea (OSA) was created from the apnea-hypopnea index (AHI), with the presence of OSA defined as an AHI Ն15. Leg movements were not recorded on overnight polysomnography. Total and high-density lipoprotein (HDL) cholesterol were obtained from baseline data provided by the SHHS parent cohorts at the SHHS baseline examination. 9
Statistical analysis. Descriptive characteristics of the study sample are presented for subjects with and without RLS. Logistic regression analyses were implemented using PROC LOGISTIC in SAS (SAS version 8.1, SAS Institute, Cary, NC) to assess the relation of RLS to prevalent CAD and CVD. Two models are presented including all 3,433 subjects for whom complete information was available for RLS, cardiovascular disease status, and key covariates: adjusted for the demographic variables age, sex, and race plus the CVD risk factors BMI, DM, SBP, use of antihypertensive medications, total: HDL cholesterol ratio, current and former smoking, and lifetime pack-years of smoking (Model 1); adjusted for the covariates in Model 1 plus AHI (Model 2). Additional analyses were performed to assess the potential impact of alcohol use (n ϭ 3,424) and caffeine consumption (n ϭ 3,388) on the association of RLS symptoms to CAD and CVD. Analyses including dichotomous variables indicating a short (Յ6 hours/night) usual sleep duration (n ϭ 3,417) or insomnia (n ϭ 3,429) were performed to assess possible mediation of the effect of RLS via reduced total sleep time. Additional analyses evaluated the relation of RLS severity to the observed association of RLS with CAD and CVD and possible effect modification by age and sex.
RESULTS
Mean age of the study sample was 67.9 years (SD ϭ 10.2, range 44 to 98), 54.6% were women, and mean BMI was 29.1 kg/m 2 (SD ϭ 5.4). Over half (56.3%) had hypertension, 12.9% had DM, 16.8% CAD, and 20.0% CVD. Median self-reported sleep onset latency was 15 minutes (IQR 10 to 30) and mean usual sleep duration was 7.1 hours (SD ϭ 1.2). Among the 2,601 subjects with home polysomnography, median AHI was 6.1 events/hour (interquartile range [IQR] 2.1 to 14.2), and 23.1% had sleep apnea as defined by an AHI Ն 15. RLS, occurring at least 5 days per month and associated with at least moderate distress, was reported by 5.2% of the sample, with women having twice the prevalence of men (6.8% vs 3.3%). Those with RLS had somewhat longer self-reported latency to sleep onset and greater self-reported sleepiness, and also more commonly had hypertension and physician-diagnosed CAD and CVD (table 1) . Subjects with RLS were also much more likely to report having nocturnal leg jerks often or almost always (31.6 vs 4.3%) and to report insomnia symptoms at least 16 nights per month (16.9 vs 8.9%). Median duration of RLS symptoms was 9 years (IQR 3 to 18). Mean age, BMI, total sleep time, caffeine consumption, and AHI, and the percentage of those with OSA, DM, or current smoking, were similar in subjects with RLS compared to those without RLS. Those with RLS were less likely to drink more than one alcoholic beverage per day.
RLS was associated with higher odds of CAD and CVD compared to those without RLS (tables 2 and 3). Older age, male sex, diabetes, total to HDL cholesterol ratio, self-reported sleep onset latency, smoking history, and use of antihyper-tensive medications were associated with significantly higher odds of CAD and CVD. Adjustments for these covariates, plus race, SBP, AHI, or usual alcohol or caffeine consumption did not attenuate the association of RLS with CAD and CVD. The association between RLS and both CAD and total CVD was similar in men and women. In analyses stratified by age, the association of RLS with CAD was stronger in those older than age 65 (OR 2.41, 95% CI 1.53 to 3.80, n ϭ 2,050) than in those under age 65 (OR 0.95, 95% CI 0.38 to 2.36, n ϭ 1,383). The effect of age was similar for total CVD. Analyses adjusted for sleep onset latency, insomnia, and usual sleep duration did not diminish the magnitude of the association of RLS with CAD and CVD, suggesting that the association was not mediated by an effect of RLS on these sleep variables. After adjustment for age, sex, race, and BMI, there was only a weak association of RLS with hypertension (OR 1.30, 95% CI 0.92 to 1.82) or diabetes mellitus (OR 1.26, 95% CI 0.79 to 2.00). After adjustment for these four covariates, there was a weak association between RLS and obstructive sleep apnea (OR 0.65, 95% CI 0.40 to 1.06) such that those with RLS had a lower probability of having an AHI Ͼ15 than those without RLS.
Additional analyses were conducted to examine the relation of RLS frequency, bothersomeness, and duration with CAD and CVD prevalence. When those with RLS were divided into those with symptoms occurring 5 to 15, 16 to 23, and Ͼ23 days per month, an association of RLS with CAD and CVD was considerably stronger in those with RLS symptoms that occurred more than 15 times per month than in those whose symptoms occurred less frequently (tables 2 and 3). Similarly, the association of RLS with CAD and CVD was stronger in those who reported that their RLS symptoms were "a lot" or "extremely" bothersome than in those who reported it to be only "moderately" bothersome (tables 2 and 3). On the other hand, among those with RLS, self-reported duration of symptoms was not significantly associated with either CAD or CVD.
DISCUSSION
The data from this communitybased epidemiologic study provide evidence that RLS is associated with an approximately twofold risk of prevalent CAD and CVD. Controlling for CVD risk factors, including age, sex, race, BMI, SBP, use of antihypertensive medications, diabetes, total:HDL cholesterol ratio, smoking history, and AHI, did not attenuate this relation. It is therefore unlikely that the observed association of RLS with CVD is due to confounding by major known CVD risk factors. Adjustment for usual alcohol or caffeine consumption, factors that have been associated with RLS in prior studies, did not influence the observed association of RLS and CVD. The observed association of RLS with CAD and CVD was evident primarily in those in whom symptoms occurred at least 16 times per month.
These findings support previous epidemiologic studies demonstrating a cross-sectional association of RLS and cardiovascular disease. Using the Wisconsin Sleep Cohort, we previously found 7 that daily RLS symptoms were associated with an OR over 2.5 for prevalent CVD, even after adjusting for age, sex, BMI, smoking, diabetes, and snoring, compared to those without RLS. However, that study did not utilize the current diagnostic criteria for RLS, and thus other disorders might have been included in the RLS group. A population-based sample of men from Sweden used responses to a mailed questionnaire to diagnose RLS in 186 individuals. 6 They also found an OR of 2.5 for RLS and self-identified "heart problems" (compared to those without RLS), after controlling for age, witnessed apneas, smoking, and alcohol consumption. Frequency of RLS symptoms was not provided. This is a cross-sectional study of RLS and prevalent CVD, and thus the data do not allow us to determine the direction of causality, if any, that exists for this association. RLS could produce CVD via autonomic changes observed with Table 1 Subject characteristics by presence of restless legs syndrome (RLS) PLMS or through other influences on sleep duration or quality. On the other hand, CVD could produce RLS via vascular changes in the CNS or in the periphery, or due to the influence of medications for CVD. Finally, a third factor (e.g., anemia, renal failure) might play a role in both RLS and CVD. Each of these potential mechanisms will be discussed in turn. RLS could increase cardiovascular risk by a number of potential mechanisms. Periodic leg movements of sleep are present in over 80% of those with RLS. Many patients with RLS have Table 2 Association of restless legs syndrome (RLS) with prevalent coronary artery disease (CAD) Values are OR (95% CI) for the association of RLS with CAD. *Severe bothersomeness represents the combination of the responses "a lot" or "extremely" bothersome. BMI ϭ body mass index; DM ϭ diabetes mellitus; SBP ϭ systolic blood pressure; LDL ϭ low-density lipoprotein; AHI ϭ apnea ϩ hypopnea index. Values are OR (95% CI) for the association of RLS with CVD. *Severe bothersomeness represents the combination of the responses "a lot" or "extremely" bothersome BMI ϭ body mass index; DM ϭ diabetes mellitus; SBP ϭ systolic blood pressure; LDL ϭ low-density lipoprotein; AHI ϭ apnea ϩ hypopnea index.
200 to 300 such leg movements per night of sleep, as well as additional involuntary movements during the waking period, especially at night. Such leg movements are associated with distinctive and substantial elevations in both blood pressure and heart rate. A 10% increase in heart rate occurs, that extends for 5 to 10 seconds after individual leg movements, 4, [12] [13] [14] and is exaggerated when EEG arousal (identified by frequency analysis) is present. 5 Similarly, large increases in systolic (20 to 30 mm Hg) and diastolic (10 to 12 mm Hg) blood pressure are present following PLMS. 15 It is noteworthy that the current data demonstrate only a weak and statistically nonsignificant association of RLS and hypertension, defined by use of antihypertensive medications or elevated systolic or diastolic blood pressure, and that adjustment for SBP and use of antihypertensive medications did not diminish the association of RLS with CAD or CVD, suggesting that this association is not mediated by hypertension. This is consistent with the null findings of previous epidemiologic studies examining the relationship of RLS and hypertension. 3, 6, 7 On the other hand, a relationship between PLMS (as recorded over multiple nights with actigraphy) and hypertension has recently been demonstrated in a large well-defined RLS cohort from Iceland (David Rye, personal communication). In the present study, RLS symptoms were strongly associated with self-reported nocturnal leg jerks, but neither polysomnographic nor actigraphic measures of PLMS were available. Although hypertension may not be the pathway by which RLS produces CVD, alternative mechanisms may be invoked for a role of the repetitive autonomic arousals seen with PLMS, such as increased coagulability or risk of plaque rupture. Alternatively, such transient blood pressure elevations could be responsible for cardiovascular events by increasing the 24hour blood pressure profile without producing changes in daytime blood pressure.
Effects on sleep quality or quantity may also mediate an effect of RLS on cardiovascular disease. Sleep disturbance is the primary clinical complaint in those with RLS, and over 60% of patients with clinically significant RLS report at least three awakenings per night and a sleep latency greater than 30 minutes 16 on nights with RLS. Recent epidemiologic studies demonstrate that sleep duration is associated with both crosssectional as well as incident cardiovascular disease. 8 In the current study, although RLS subjects did have longer self-reported sleep latency, total sleep time was similar in the two groups. More-over, inclusion of sleep latency, usual total sleep duration, or insomnia into the regression model did not affect the ORs for the association of RLS with CAD or CVD, suggesting that insomnia is not on the causal pathway between RLS and these outcomes.
CVD could also cause RLS. Vascular alterations in the CNS or in the peripheral vasculature might produce RLS symptoms. Similarly, medications used in the treatment of CVD (e.g., antihypertensives, anti-anginals) might cause RLS, though such an association has not been demonstrated to date. Although antihypertensives were more commonly used by those with RLS than those without RLS in the current study, adjustment for antihypertensive medication use had no appreciable effect on the ORs.
Although there was no meaningful attenuation of the RLS-CVD association with extensive adjustment for known cardiovascular risk factors, it remains possible that confounding by unmeasured nutritional, metabolic, or exercise-related factors might play a role in both RLS and CVD (e.g., iron deficiency, renal failure). Certainly, the latter disorders can predispose to cardiovascular disease and are known secondary causes of RLS. On the other hand, renal failure is present in only 0.1% of the population, and it is unlikely that such a small number of subjects would substantially influence the association observed in this cohort. Similarly, none of the epidemiologic studies using face to face RLS diagnoses that measured hemoglobin indices found that anemia was present in a greater proportion of RLS subjects than in the general population. [17] [18] [19] Thus, while it is possible that anemia is responsible for the association observed in our data, we believe that it is unlikely. Of note, it is subtle iron abnormalities, and in particular, CNS iron dysregulation, that characterizes RLS. Finally, exclusion of subjects taking dopaminergic agents or benzodiazepines did not diminish the association of RLS and CVD.
Our finding that RLS symptom frequency is associated with CAD and total CVD risk primarily when it exceeds 15 times per month adds to our emerging understanding of RLS outcomes as a function of RLS frequency and severity. The primary care-based REST study 16 identified "RLS sufferers" as those whose RLS symptoms occur at least twice per week with at least some negative impact on quality of life. Such RLS sufferers had higher rates of physician-diagnosed insomnia or other sleep disorders, neuropathy, and depressed mood or depression, but not cardiovascular disorders or hypertension, than those with RLS at least once per week but without an effect on qual-ity of life. In a previous population-based study, using another middle aged and elderly cohort, 7 we demonstrated an elevated risk of CVD in those with daily RLS symptoms (without a quality of life impact threshold), but not in those with symptoms occurring only one to six times per week. RLS patients with end-stage renal disease (ESRD) who were "very bothered" or "extremely bothered" by their RLS had a 39% increased risk in 3-year mortality compared to ESRD patients without RLS, whereas this association was not observed in those with less bothersome symptoms. 20 In the current study, we similarly found that bothersomeness influenced the estimated OR for CAD and CVD. Thus, it appears that both frequency and bothersomeness of symptoms may influence the cardiovascular consequences of RLS. Future studies should further assess the independent effects of these two measures of disease severity.
Several limitations should be considered when assessing the findings of this study. RLS diagnosis was made by questionnaire rather than by interview. Although the questionnaire reflects currently accepted diagnostic criteria, it is probable that some subjects without RLS, but with clinical mimics such as leg cramps, diabetic neuropathy, and arthritis, were included in the RLS group, and that these subjects may have inflated the association between the RLS group and CVD. The SHHS is a study of middle aged and older subjects with a minimum age of 44 years. Analyses stratified by age above or below 65 years suggest an effect modification by age, with the association of RLS and CVD seen only in the older age stratum. Thus, the results may not be generalizable to younger individuals, although it may be that any RLS-related increase in cardiovascular risk has a long latent period. Similarly, as 80% of the sample was white, it is unclear whether these results can be generalized to nonwhite patients.
